American Association for Cancer Research Annual Meeting 2024
New clinical data at AACR (FIG. 1 📸):
April 7, 2024
Replimune Group Inc. (NASDAQ: REPL)
Drug Name: RP1
Indication: Cutaneous squamous cell carcinoma
Trial Stage: Ph 1/2
Kazia Therapeutics Limited (NASDAQ: KZIA)
Drug Name: EVT801
Indication: Advanced Solid Tumors
Trial Stage: Ph 1
April 8, 2024
Poseida Therapeutics, Inc. (NASDAQ: PSTX)
Drug Name: P-BCMA-ALLO1
Indication: Multiple Myeloma
Trial Stage: Ph 1/2
Drug Name: P-MUC1C-ALLO1
Indication: Ovarian cancer, Breast cancer
Trial Stage: Ph 1
April 9, 2024
BeiGene (NASDAQ: BGNE)
Drug Name: Ociperlimab + tislelizumab
Indication: limited stage-SCLC
Trial Stage: Ph 2
Medicenna Therapeutics (NASDAQ: MDNA)
Drug Name: MDNA11
Indication: Cold tumors
Trial Stage: Ph 1/2
RAPT Therapeutics (NASDAQ: RAPT)
Drug Name: Tivumecirnon/FLX475
Indication: Non-small cell lung carcinoma
Trial Stage: Ph 2
Fusion Pharmaceuticals (NASDAQ: FUSN)
Drug Name: FPI-2265
Indication: Prostate Cancer
Trial Stage: Ph 2
Purple Biotech (NASDAQ: PPBT)
Drug Name: NT219
Indication: Head and neck squamous cell carcinoma
Trial Stage: Ph 1
Atossa Therapeutics (NASDAQ: ATOS)
Drug Name: (Z)-endoxifen
Indication: Breast Cancer
Trial Stage: Ph 2
April 10, 2024
Lantern Pharma (NASDAQ: LTRN)
Drug Name: LP-284
Indication: Non-Hodgkin's Lymphoma
Trial Stage: Ph 1
BioNTech (NASDAQ: BNTX)
Drug Name: BNT122 w/ atezolizumab and chemotherapy
Indication: Pancreatic cancer
Trial Stage: Ph 1
Drug Name: BNT116 +/- cemiplimab
Indication: Non-small cell lung carcinoma
Trial Stage: Ph 1
FIG. 1. Upcoming data readouts at AACR '24
---
Get a list of all recently funded companies with deeper info to help your sales/BD activities. Contact us to learn more
Article History:
RF & DV (04/04/24)
Comentários